ArticleJournal, genetic engineering & biotechnology2025
The evaluation of a novel multi-epitope vaccine against human papillomavirus and Candida albicans.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RethinkingVaccines · 2026Review
- Perspectives on Vaginal Ecology and Management of Recurrent Vulvovaginal Candidiasis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to design and evaluate a multiepitope peptide vaccine against Human papillomavirus (HPV) and Candida albicans (C. albicans) on human dendritic cells (hDC).
methodsTo determine the antigenic epitopes for C. albicans and HPV, the FASTA format of protein targets was extracted from NCBI. Then, all epitopes were analyzed using ABCpred, Vaxijen, AllerTOP, ToxinPred, and molecular docking. Then, selected peptides were first synthesized using the solid phase method, mixed with cationic lipids, and characterized by DLS, Zetasizer, and nanodrop at 280 nm. In the next step, hDCs were obtained from peripheral blood and confirmed by flow cytometry. Then, they were exposed to vaccine candidates at 1 mg/mL. Next, the activation of hDC was checked by the expression and concentration of interleukin-12 (IL-12) and interferon-ɣ (IFN-ɣ). Also, the functionality of hDCs and antigen-loaded hDCs was evaluated by their ability to induce the proliferation of allogeneic T cells by mixed lymphocyte reaction (MLR). Finally, antibody titration against vaccine candidates was investigated on Syrian male mice using the ELISA method.
resultsHere, KDIDLDLQEL, GPVLALNVAL, and KDIDLDLQELKKKGPVLALNVAL peptides were selected as E7, HYR1, and merged E7-HYR1 peptides, respectively. We found that more than 85 % of the isolated hDCs were positive for HLA-DR, CD86, and CD209 and less than 5 % were positive for CD14. After treatment of hDCs with vaccine candidates, we found that peptides E7, HYR1, and merged E7-HYR1 could stimulate hDCs to express IL-12 and IFN-ɣ and when the selected peptides integrated into nanoliposomes, they were significantly more capable to stimulate hDC (P < 0.05). Also, we found that the stimulation index of vaccine-loaded hDCs was higher than unloaded hDCs. The antibody titer in mice exposed to nanoliposomes was significantly higher than in mice exposed to specific peptide vaccines.
conclusionHere, a multiepitope peptide vaccine against HPV and C. albicans was designed and evaluated on hDC. Real efficacy and side effects of this vaccine must be analyzed in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.